LPCN - Lipocine shares up after LPCN 1144 preclinical study results

Lipocine (LPCN) shares rise nearly 6% premarket after announcing the publication of preclinical results supporting the therapeutic potential of LPCN 1144 in the treatment of and non-alcoholic steatohepatitis ("NASH") and hepatic fibrosis.The results were featured in a paper entitled "Treatment Potential of LPCN 1144 on Liver Health and Metabolic Regulation in a Non–Genomic, High Fat Diet Induced NASH Rabbit Model", published in the Journal of Endocrinological Investigation.The Journal pointed towards positive data from the study and argued that the preclinical findings support a therapeutic potential of LPCN 1144 in the treatment of NASH and of hepatic fibrosis.

For further details see:

Lipocine shares up after LPCN 1144 preclinical study results